BioCentury | Dec 1, 2016
Emerging Company Profile

Safe arrest

...their high toxicity in normal, non-dividing cells presents a large side effect burden to patients. Diazon Pharmaceuticals...
...within a year and will take DZ-2384 through Phase II testing before partnering. COMPANY PROFILE Diazon Pharmaceuticals Inc....
...President: Michael Dixon Patents: 2 issued covering the lead compound DZ-2384 Companies and Institutions Mentioned Diazon Pharmaceuticals Inc....
Items per page:
1 - 1 of 1
BioCentury | Dec 1, 2016
Emerging Company Profile

Safe arrest

...their high toxicity in normal, non-dividing cells presents a large side effect burden to patients. Diazon Pharmaceuticals...
...within a year and will take DZ-2384 through Phase II testing before partnering. COMPANY PROFILE Diazon Pharmaceuticals Inc....
...President: Michael Dixon Patents: 2 issued covering the lead compound DZ-2384 Companies and Institutions Mentioned Diazon Pharmaceuticals Inc....
Items per page:
1 - 1 of 1